<DOC>
	<DOCNO>NCT02022917</DOCNO>
	<brief_summary>This study determine feasibility postoperative platinum-based chemotherapy plus adjuvant maintenance bevacizumab neoadjuvant chemotherapy follow interval surgery patient extensive stage IIIC IV ovarian , tubal , peritoneal cancer .</brief_summary>
	<brief_title>Postoperative Adjuvant Chemotherapy With Bevacizumab Maintenance Bevacizumab After Neoadjuvant Chemotherapy Ovarian Cancer</brief_title>
	<detailed_description>This study design determine feasibility administer adjuvant carboplatin , paclitaxel , bevacizumab without unacceptable significant AE patient epithelial ovarian cancer neoadjuvant carboplatin/cisplatin , paclitaxel interval cytoreductive surgery , primary peritoneal cancer fallopian tube cancer . This study also investigate progression free ass quality life . A Simon minimax two-stage design employ determine permit early stopping moderately long sequence initial adverse event occur . Under two-stage design , 13 subject enrol first stage . If &gt; 3 subject discontinue treatment due significant AE stage-1 , stop trial . Otherwise , second stage implement include 14 subject . The treatment safety evaluate ensured occurrence rate significant AE ( non AE ) . In stage-1 , postoperative adjuvant cycle 2-6 observe defined significant AE . Patients ' physician ' decision discontinuation above-defined significant AEs due cancer progression count end-point event .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1. histologically proven epithelial ovarian cancer , tubal peritoneal primary carcinoma , FIGO stage IV extensive stage III deem feasible primary cytoreductive surgery # 2. histologic epithelial cell type follow : Serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant Brenner 's Tumor , adenocarcinoma otherwise specify ( N.O.S. ) . 3. well inform rationale neoadjuvant chemotherapy alternative upfront surgery follow adjuvant chemotherapy accept treatment three four cycle neoadjuvant platinumbased regimen without progression follow interval cytoreductive surgery 4. performance status ECOG 02 5. adequate hematopoietic function define : ANC ≦ 1,500/uL , equivalent Common Toxicity Criteria Adverse Events v4.03 ( CTCAE ) Grade1 . Platelets ≦ 100,000/uL ( CTCAE Grade 01 ) . INR ≦ 1.5 ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin ) aPTT &lt; 1.2 x ULN 6. adequate organ function define : total bilirubin ≦ 1.5 × ULN ( CTCAE Grade 1 ) . ALT/AST≦2.5 x ULN alkaline phosphatase≦2.5 x ULN ( CTCAE Grade 1 ) serum creatinine ≦ 1.5 × ULN ( CTCAE Grade 1 ) . 7. adequate neurologic function , neuropathy ( sensory motor ) ≦ CTCAE Grade 1 8. age 2075 year old 9 . Patients may measurable nonmeasurable disease . Patients may may cancerrelated symptom . 10. life expectancy equal longer 3 month 11 . Patients meet preentry requirement 12. ability understand willingness sign write informed consent document ( within 3 week interval surgery ) 1. borderline ovarian tumor , recurrent epithelial ovarian , tubal peritoneal nonepithelial cancer 2. history evidence upon physical examination CNS disease , include primary brain tumor , seizures control standard medical therapy , brain metastasis , history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarrachnoid hemorrhage within six month first date treatment study . 3 . Patients synchronous primary endometrial cancer , past history primary endometrial cancer , exclude . 4. malignancy exception curative treat nonmelanoma skin cancer cervical carcinoma situ within 5 year prior enter study 5. patient receive targeted therapy ( include limit vaccine , antibody , tyrosine kinase inhibitor ) hormonal therapy management ovarian , peritoneal primary fallopian tube carcinoma 6. patient serious , nonhealing wound , ulcer , bone fracture . 7. patient granulate incision heal secondary intention evidence fascial dehiscence infection eligible require weekly wound examination . 8. history abdominal fistula , gastrointestinal perforation , intraabdominal abscess active gastrointestinal bleeding within 6 month . 9. patient active bleed pathologic condition carry high risk bleeding , know bleed disorder , coagulopathy , tumor involve major vessel 10. clinically significant proteinuria . Urine protein screen urine proteincreatinine ratio ( UPCR ) . The UPCR find correlate directly amount protein excreted 24 hour urine collection . Specifically , UPCR 1.0 equivalent 1.0 gram protein 24 hour urine collection . Obtain least 4 ml random urine sample sterile container ( 24 hour urine ) . Send sample lab request urine protein creatinine level [ separate request ] . The lab measure protein concentration ( mg/dL ) creatinine concentration ( mg/dL ) The UPCR derive follow : protein concentration ( mg/dL ) /creatinine ( mg/dL ) . Patients must UPCR &lt; 1.0 allow participation study . 11. clinical significant cardiovascular disease Uncontrolled hypertension , define systolic &gt; 150 mm Hg diastolic &gt; 90 mm Hg . Prior history hypertensive crisis hypertensive encephalopathy active cardiac disease e.g . decompensated myocardial infarction within 6month period precede entry study . New York Heart Association ( NYHA ) Grade II great congestive heart failure serious cardiac arrhythmia require medication . CTCAE Grade 2 great peripheral vascular disease ( least brief ( 24 hr ) episodes ischemia manage nonsurgically without permanent deficit ) History CVA within six month . 12. known hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibody 13. presence serious concomitant illness affect elevate value CA125 14. acute hepatitis active infection require parenteral antibiotic 15. anticipation invasive procedure define : Major surgical procedure , open biopsy significant traumatic injury within 28 day prior first date Bevacizumab ( cycle 2 ) . Major surgical procedure anticipate course study . Core biopsy within 7 day prior first date Bevacizumab ( cycle 2 ) . 16 . Patients receive prior radiotherapy portion abdominal cavity pelvis exclude . Prior radiation localize cancer breast , head neck , skin permit , provide complete three year prior registration , patient remain free recurrent metastatic disease . 17. concurrent chemotherapy , radiotherapy , investigational drug except nondisease relate condition ( e.g . insulin diabetes ) study period 18. mental status fit clinical trial 19 . Patients pregnant nursing . Subjects childbearing age use effective mean contraception</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>ovarian cancer .</keyword>
	<keyword>tubal cancer</keyword>
	<keyword>peritoneal cancer</keyword>
</DOC>